As Washington’s interest in drug prices has spiked in recent years, a largely invisible industry has suddenly found itself in the spotlight. Pharmacy benefit managers, or PBMs, are the middlemen who stand between manufacturers and consumers in the nation’s drug business. And they’ve been blamed by pharma companies for being the real profiteers in the current pricing system.

It seems at least some of that message is resonating with politicians. Last week the president’s council of economic advisers released a report on drug prices that raised alarms about PBM consolidation and called for policy changes to encourage competition.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Although I support measures such as banning gag clauses in PBM contracts, at root the PBMs are not the main cause of too-high drug prices . . . pharmaceutical companies are. And Pharma is trying to divert us by throwing shade on PBMs.

    PBMs have now become part of the current environment with a vested interest in its continuance, and some of the measures they use to bring down drug prices have bad effects (making drugs preferred formulary drugs can be stressful on patients who have to switch for NO clinical reason), but at root they are part of the self-defense ecology of insurers battling Pharma’s ever-increasing, abusive drug prices.

    We need to focus most pressure on Pharma, not PBMs.

  • Let’s see how much guys and hutzpah Washington has when in our legalized corrupt system every legislator is on the game. linked article quickly walks through few drugs and pricing I the US and India. https://pharmachemicalscoatings.blogspot.com/2018/01/comparison-of-drugs-prices-us-vs-india_89.html?m=1

    Generally in every profitable business the producer should make profit and that their birth right for survival. But exploiting the system in false pretense should be unethical.

    For every drug, take a generic Ciprofloxacin, active has to be produced that is sold at a profit to a formulator who then sells it at a profit. Again, their birth right.

    In linked article I have used Ciprofloxacin as an example. Today I had to buy 20 of 500 milligram tablets. In India price is about 5 cents a tablet. If one can buy it at WalMart it is about 17 cents a tablet. However due to insurance coverage I paid 50 cents and had no choice.

    I got curious and asked, what I have prescription but no insurance, what would be the price. It was $4.25 cents per tablet. Isn’t that a broad day light robbery or rape or whatever choice words one wants to use.

    Amazon, Berkshire and JPMorgan (ABM = anti ballistic missile alloance) want bring the prices down but PBMs have already made sure they are not touched. They has already been told don’t meddle.

    Let’s see which legislator has any gut and if they do their epitah will be writen fast and furious. Cheers.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy